Department of Radiation Oncology, University of Washington, Seattle, Washington.
Department of Radiation Oncology, University of Washington, Seattle, Washington.
Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):564-571. doi: 10.1016/j.ijrobp.2020.04.047. Epub 2020 May 11.
To characterize the participation of radiation oncology (RO) in reporting quality metrics through the Centers for Medicare and Medicaid Services' (CMS) Hospital Compare database and to describe the association of hospital characteristics with RO-specific quality metrics.
Data from the CMS Hospital Compare, International Atomic Energy Agency's Directory of Radiotherapy Centre, 2010 US Census, and CMS Inpatient Prospective Payment System were linked to create an integrated data set of geographic information, facility characteristics, and quality measures, focusing on the use of external beam radiation therapy (EBRT) for bony metastases.
Of 4829 hospitals in the Hospital Compare database, 2030 had access to radiation therapy. Among these, 814 (40%) reported on the rate of guideline-concordant EBRT for bony metastases, a RO-specific quality measure. A total of 33,614 eligible cases of bony metastases treated with EBRT were sampled. Participation in quality reporting varied significantly by geography, population type, teaching status, hospital ownership, hospital type, and hospital size. The median rate of guideline-concordant palliative EBRT utilization was 89%. Nine percent of 814 centers had a compliance rate of less than 50%. On multivariable analysis, increasing number of cases sampled (odds ratio 0.93, P = .028), increasing hospital star-rating, and above-average patient experience rating (odds ratio 0.58, P = .024) remained significantly associated with decreased odds of falling into the lowest quartile of guideline-concordant EBRT utilization.
RO participation in a large, national quality improvement effort is nascent and reveals potential quality gaps between hospitals offering palliative EBRT for bone metastases. More robust RO-specific quality measures are needed.
通过医疗保险和医疗补助服务中心(CMS)的医院比较数据库来描述放射肿瘤学(RO)在报告质量指标方面的参与情况,并描述医院特征与 RO 特定质量指标之间的关系。
将 CMS 医院比较、国际原子能机构放射治疗中心名录、2010 年美国人口普查和 CMS 住院患者预付款制度的数据链接起来,创建了一个地理信息、设施特征和质量指标的综合数据集,重点是外部束放射治疗(EBRT)治疗骨转移。
在 CMS 医院比较数据库中的 4829 家医院中,有 2030 家可以进行放射治疗。在这些医院中,有 814 家(40%)报告了骨转移的指南一致的 EBRT 率,这是一个 RO 特定的质量指标。共抽样了 33614 例接受 EBRT 治疗的骨转移患者。参与质量报告的情况因地理位置、人口类型、教学状态、医院所有权、医院类型和医院规模而有显著差异。指南一致的姑息性 EBRT 使用率中位数为 89%。814 个中心中有 9%的符合率低于 50%。在多变量分析中,样本量增加(优势比 0.93,P =.028)、医院星级评分增加和患者体验评分高于平均水平(优势比 0.58,P =.024)与较低的指南一致 EBRT 使用率的四分位数的几率降低显著相关。
RO 参与到一项大型的国家质量改进工作中还处于初级阶段,这揭示了提供姑息性 EBRT 治疗骨转移的医院之间存在潜在的质量差距。需要更严格的 RO 特定质量指标。